Monlutenca (Lutetium (177lu) Chloride)

It is a beta‑emitting radionuclide that, when attached to a ligand that binds tumor‑specific receptors, delivers localized radiation. The beta particles cause DNA damage within a short range, leading to tumor cell death while sparing surrounding healthy tissue; gamma emissions also enable imaging.

The prescribed dose of Monlutenca is determined individually by the treating physician based on factors such as tumor type, receptor expression, body weight, and renal function. Dosage regimens are established in accordance with clinical guidelines and regulatory approvals.

Safety data for Lutetium‑177 chloride in pregnancy and lactation are limited. It is generally contraindicated unless the potential therapeutic benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception and discuss risks with their healthcare provider.

To request Monlutenca, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Compared with alternative agents such as Yttrium‑90 or Iodine‑131 based therapies, Lutetium‑177 offers a shorter tissue penetration depth, allowing more precise tumor targeting with reduced collateral damage. Its gamma emission also facilitates post‑treatment imaging, providing an advantage for treatment monitoring.

Monlutenca should be stored at ambient temperature, below 25 °C, in its original sealed container, protected from moisture and direct light. Handling must follow radiation safety protocols, and personnel should wear appropriate protective equipment to avoid contamination.

Monlutenca is administered intravenously by a qualified healthcare professional, typically as an infusion over a short period under controlled conditions. The exact administration procedure, including infusion rate and pre‑medication, is defined by the prescribing physician and institutional protocols.

The most serious risks include severe myelosuppression leading to infections or bleeding, renal toxicity that may impair kidney function, and rare radiation‑induced secondary malignancies. Patients should be monitored closely with regular blood tests and renal assessments throughout treatment.

Monlutenca is contraindicated in patients with known hypersensitivity to Lutetium‑177 chloride or its excipients, those lacking the appropriate tumor receptor expression, individuals with severe renal impairment, and pregnant or nursing women unless the therapeutic benefit outweighs the risk.